Table 4 OR and 95% CI values of different inflammatory parameters used as prognostic indicators in metastatic PC submitted to ADT or in metastatic CRPC

Serum levels

IL-8

[61]

Phase II study in metastatic PC submitted to ADT

IL-8 and overall survival or TNF alpha and overall survival

1.9 (1.0–3.5)

0.04

2.0 (1.1–3.5)

0.02

Systemic inflammation NLR

[62]

Phase II study on CRPC submitted to docetaxel

NLR and overall survival

1.65 (1.25–2.18)

<0.001

Systemic inflammation and NLR

[63]

Phase II study on CRPC submitted to carbazitaxel

NLR and overall survival

1.91 (1.31–2.79)

0.001

Systemic inflammation NLR

[64]

Phase III study on CRPC submitted to docetaxel

NLR and risk of death

1.29 (1.11–1.50)

<0.001

Systemic inflammation NLR

[65]

Phase II study on CRPC submitted to sunitinib

NLR and overall survival

1.55 (1.32–1.83)

<0.01

Systemic inflammation NLR

[65]

Phase II study on CRPC submitted to abiraterone

NLR and PSA progression

4.3 (1.4–13.3)

0.01

Systemic inflammation CRP

[66]

Phase II study on CRPC submitted to docetaxel

CRP and risk of tumor progression or risk of death

2.18 (1.40–3.40)

0.001

2.0 (1.28–3.12)

0.002

Systemic inflammation mGPS

[67]

Phase II study on CRPC submitted to docetaxel

mGPS and overall survival

1.87 (1.35–2.59)

<0.001